Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571479 | 1.00 | NPC1 (0.36) | NPC1DGAT1GRM2TP53KDM4E | |
| SCHEMBL26348707 | 0.85 | NPC1 (0.37) | NPC1DGAT1TP53RAB9A | |
| SCHEMBL30436067 | 0.84 | NPC1 (0.35) | NPC1DGAT1F2RL1 | |
| SCHEMBL20745601 | 0.84 | NPC1 (0.35) | NPC1DGAT1F2RL1 | |
| SCHEMBL4762700 | 0.84 | NPC1 (0.38) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL26128948 | 0.83 | NPC1 (0.41) | NPC1DGAT1KDM4ERAB9AEGFR | |
| SCHEMBL25298512 | 0.83 | EGFR (0.37) | NPC1DGAT1GRM2TP53KDM4E | |
| SCHEMBL31276772 | 0.83 | DGAT1 (0.37) | NPC1DGAT1 | |
| SCHEMBL20753970 | 0.83 | NPC1 (0.38) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL30565986 | 0.83 | EGFR (0.37) | NPC1DGAT1GRM2TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406612-B1 | CARBOLINE DERIVATIVE SERVING AS BROMODOMAIN INHIBITOR | NINGBO WENDA PHARMA TECH LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-10907197-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3190888-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3190888-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-3190888-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016033460-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | NPC1 2440/4885DGAT1 4110/4885GRM2 3328/4885 |
| US-10907197-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | NPC1 112/4885DGAT1 2727/4885GRM2 1348/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | NPC1 2367/4885DGAT1 4003/4885GRM2 3383/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | NPC1 1074/4885DGAT1 3611/4885GRM2 3298/4885 |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | NPC1 112/4885DGAT1 2727/4885GRM2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.